Search for: "Apotex Inc."
Results 401 - 420
of 674
Sorted by Relevance
|
Sort by Date
23 Jan 2024, 3:43 am
Apotex (Fed. [read post]
28 Jul 2010, 12:06 am
Apotex Inc. et al. [read post]
31 Jul 2015, 4:30 am
A simple song with a complex copyright history and lawsuit http://t.co/89sehViGAE -> New survey says cybersecurity worries among execs have risen sharply, promotes more info sharing http://t.co/B9Zprv5igJ -> David Cameron warns porn websites to block under-18s or face legal curbs http://t.co/ppjHbJRrd4 -> RIAA and Friends Accuse CNET of Hosting 'Pirate' Software http://t.co/XFxw6BQ4y2 -> Chinese Hackers Reportedly Hit United Airlines http://t.co/NCJhK51L7Q -> Federal Court… [read post]
16 Nov 2011, 10:00 am
Generic olanzapine orally disintegrating tablets will be manufactured by Apotex Inc., Dr. [read post]
11 Nov 2017, 11:00 am
Apotex, Inc., 633 F.3d 1042,1056 (Fed. [read post]
18 Sep 2016, 6:03 pm
Another new petition includes the BPCIA case Apotex v. [read post]
21 Jun 2016, 4:00 am
(paras 36-37) [11] At May 12, 2016 CBA IP Day in Ottawa [12] Astra v Apotex SCC 36654 (leave granted March 10, 2016) http://www.scc-csc.ca/case-dossier/info/resul [read post]
23 Sep 2016, 7:12 am
Apotex Corp., 782F.3d 1324, 1333 (Fed. [read post]
8 Oct 2013, 2:52 pm
Apotex Inc., 687 F.3d 1362, 1367 (Fed. [read post]
4 Apr 2012, 8:53 am
Apotex Corp., 439 F.3d 1312, 1320 (Fed. [read post]
10 Aug 2011, 4:30 am
(Patent Docs) Relpax (Eletripian hydrobromide) – Pfizer settles Relpax infringement suit with Apotex (Patent Docs) Solodyn (Minocycline) – US: Medicis and Lupin settle Solodyn infringement dispute; Agree to drug development collaboration (Patent Docs) Viagra (Sildenafil citrate) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. [read post]
27 Oct 2014, 5:13 am
Les Laboratoires Servier & Anor v Apotex Inc & Ors, heard 10 June 2014. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
28 Nov 2008, 12:49 pm
victories in fight for European BRCA patents (Holman's Biotech IP Blog) Europe: European Commission proposes strategy for dealing with rare diseases (Pharmacapsules @ Gowlings) US: Former House Ways and Means Economist claims 7-year data exclusive period is sufficient (Patent Docs) US: Medco predicts follow-on biologics regulatory pathway by 2011 (Patent Docs) US: Even after patent has expired, District Court has jurisdiction to set exclusivity date: In re Omeprazole Patent Litigation… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
14 May 2015, 4:00 am
In Eli Lilly Canada Inc. v. [read post]
15 Oct 2019, 2:09 am
Apotex, Inc., the Federal Circuit reversed the PTAB’s determination that a Tarceva® patent was invalid as obvious because the decision was not supported by a reasonable expectation of success. [read post]
22 May 2015, 10:38 am
They claimed damages under the cross undertaking given by AstraZeneca, seeking £32 million in respect of their losses.The law on the calculation of damages under a cross-undertakingIn his January 2014 judgment, Sales J referred to the judgment of Norris J in Les Laboratoires Servier v Apotex Inc [2008] EWC 2347, [2009] FSR 3 as explaining the general principles to be applied when assessing the damages payable under a cross-undertaking. [read post]
10 Dec 2014, 4:00 am
That question was answered by the Federal Court in Drexan Energy Systems Inc. v. [read post]
23 Jul 2017, 4:00 am
Apotex Inc., 2017 SCC 36 (36654) The Promise Doctrine is not the correct approach to determine whether a patent has sufficient utility. [read post]
